Related references
Note: Only part of the references are listed.Important therapeutic targets in chronic myelogenous leukemia
Hagop M. Kantarjian et al.
CLINICAL CANCER RESEARCH (2007)
Chronic myeloid leukemia:: Diagnosis and treatment
Alfonso Quintas-Cardama et al.
MAYO CLINIC PROCEEDINGS (2006)
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
H Kantarjian et al.
BLOOD (2004)
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
M Hardling et al.
MEDICAL ONCOLOGY (2004)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
J Cortes et al.
CANCER (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
HM Kantarjian et al.
BLOOD (2003)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
